Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma
Marta Santisteban (1), José Luis Pérez-Gracia (1), Jaime Ceballos (1), Isabel Vivas (2) and Jesús García-Foncillas (1)
We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance. Prior chemotherapy regimens included docetaxel plus estramustine and oral etoposide.
To our knowledge, this is the first report that shows this approach in an HRPC patient.
CITATION Clin Transl Oncol. 2008 Jun;10(6):372-4. doi: 10.1007/s12094-008-0214-9